- Home
- DSM vs SGHT Comparison
DSM vs SGHT Comparison
Compare DSM & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- SGHT
- Stock Information
- Founded
- DSM 1989
- SGHT 2011
- Country
- DSM United States
- SGHT United States
- Employees
- DSM N/A
- SGHT N/A
- Industry
- DSM Investment Managers
- SGHT Medical Specialities
- Sector
- DSM Finance
- SGHT Health Care
- Exchange
- DSM Nasdaq
- SGHT Nasdaq
- Market Cap
- DSM 303.5M
- SGHT 304.4M
- IPO Year
- DSM N/A
- SGHT 2021
- Fundamental
- Price
- DSM $6.12
- SGHT $3.87
- Analyst Decision
- DSM
- SGHT Buy
- Analyst Count
- DSM 0
- SGHT 7
- Target Price
- DSM N/A
- SGHT $6.58
- AVG Volume (30 Days)
- DSM 161.7K
- SGHT 249.8K
- Earning Date
- DSM 01-01-0001
- SGHT 11-07-2024
- Dividend Yield
- DSM 3.97%
- SGHT N/A
- EPS Growth
- DSM N/A
- SGHT N/A
- EPS
- DSM N/A
- SGHT N/A
- Revenue
- DSM N/A
- SGHT $79,543,000.00
- Revenue This Year
- DSM N/A
- SGHT $2.18
- Revenue Next Year
- DSM N/A
- SGHT $8.14
- P/E Ratio
- DSM N/A
- SGHT N/A
- Revenue Growth
- DSM N/A
- SGHT N/A
- 52 Week Low
- DSM $4.69
- SGHT $2.58
- 52 Week High
- DSM $6.05
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- DSM 55.38
- SGHT 39.20
- Support Level
- DSM $6.09
- SGHT $3.65
- Resistance Level
- DSM $6.18
- SGHT $4.11
- Average True Range (ATR)
- DSM 0.05
- SGHT 0.19
- MACD
- DSM 0.02
- SGHT 0.06
- Stochastic Oscillator
- DSM 73.91
- SGHT 27.50
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.